Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: A randomized clinical trial in 509 patients

被引:108
|
作者
Bal, CS [1 ]
Kumar, A [1 ]
Pant, GS [1 ]
机构
[1] All India Inst Med Sci, Dept Nucl Med, New Delhi 110029, India
来源
关键词
D O I
10.1210/jc.2003-031152
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Remnant ablation can be achieved by either administering an empiric fixed dose or using dosimetry-guided techniques. Because of the technical and logistic difficulties, most centers have adapted the fixed-dose or standard-dose technique for remnant ablation using (131)I. In the late 1970s, low- dose (131)I remnant ablation was introduced, and subsequently many centers confirmed the effectiveness of such therapy. However, the optimal dose (administered activity) of (131)I for remnant ablation is not yet settled. In a randomized clinical trial to find out the smallest possible effective dose for remnant ablation in cases of differentiated thyroid carcinoma, between July 1995 and January 2002, 565 patients were randomized into eight groups according to (131)I administered activity, starting at 15 mCi and increasing activity in increments of 5 mCi until 50 mCi. In the postrandomization phase, 56 patients were excluded from the study for various reasons, and final analysis was done with 509 patients. The mean age of the patients was 37.5+/-12.7 yr with a female to male ratio of 2.6. The surgical procedure was total/near-total thyroidectomy in 72% and subtotal or hemithyroidectomy in the rest. Histology was papillary thyroid carcinoma in 80.6% of patients and follicular thyroid carcinoma in the rest. With one dose of (131)I, remnant ablation was achieved in 59.6, 63.6, 81.4, 83.6, 79.4, 78.3, 84.4, and 81.8% of patients in the 15- to 50-mCi groups, respectively (overall ablation rate, 77.6%). The successful ablation rate was statistically different in patients receiving less than 25 mCi of (131)I compared with those receiving at least 25 mCi [63 of 102 (61.8%) vs. 332 of 407 (81.6%); P=0.006]. However, there was no significant intergroup difference in outcome among patients receiving 25-50 mCi of (131)I. Patients with small tumor size (less than or equal to5 cm), adequate surgery (total/near-total thyroidectomy), and radioiodine neck uptake of less than or equal to 10% had odds ratios of 2.4 [confidence interval (CI), 1.3-3.98], 2.6 (CI, 1.6-4.2), and 2.2 (CI, 1.4-3.5), respectively, for successful remnant ablation. Patients receiving at least 25 mCi of (131)I had a three times better chance of getting remnant ablation than patients receiving lesser activity of (131)I. Any activity of (131)I between 25 and 50 mCi appears to be adequate for remnant ablation.
引用
收藏
页码:1666 / 1673
页数:8
相关论文
共 50 条
  • [21] Adjuvant thyroid remnant ablation in patients with differentiated thyroid carcinoma confined to the thyroid: a comparison of ablation success with different activities of radioiodine (I-131)
    Prpic, Marin
    Dabelic, Nina
    Stanicic, Josip
    Jukic, Tomislav
    Milosevic, Milan
    Kusic, Zvonko
    ANNALS OF NUCLEAR MEDICINE, 2012, 26 (09) : 744 - 751
  • [22] Adjuvant thyroid remnant ablation in patients with differentiated thyroid carcinoma confined to the thyroid: a comparison of ablation success with different activities of radioiodine (I-131)
    Marin Prpic
    Nina Dabelic
    Josip Stanicic
    Tomislav Jukic
    Milan Milosevic
    Zvonko Kusic
    Annals of Nuclear Medicine, 2012, 26 : 744 - 751
  • [23] Postoperative radioiodine ablation in patients with low risk differentiated thyroid carcinoma
    Diez, Juan J.
    Grande, Enrique
    Iglesias, Pedro
    MEDICINA CLINICA, 2015, 144 (01): : 35 - 41
  • [24] Thyroid remnant ablation of differentiated thyroid carcinoma: a comparison of ablation success with high and low doses of radioiodine (I-131)
    Elrasad, S. A. A.
    Abdelhafeez, Y.
    Husseini, M. A.
    Amin, R. A. A.
    Elrefaei, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S328 - S328
  • [25] Fractionated dosage of radioiodine for the ablation of differentiated thyroid carcinoma
    Czepczynski, R
    Ziemnicka, K
    Baczyk, M
    Oleksa, R
    Ruchala, M
    Sowinski, J
    THYROID, 2005, 15 (11) : 1261 - 1265
  • [26] Thyroid remnant ablation in differentiated thyroid carcinoma: When and how
    Verburg F.A.
    Hänscheid H.
    Luster M.
    Clinical and Translational Imaging, 2013, 1 (3) : 195 - 203
  • [27] POSTSURGICAL THYROID REMNANT ESTIMATION BY 99mTc-PERTECHNETATE SCINTIGRAPHY PREDICTS RADIOIODINE ABLATION EFFECTIVENESS IN PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA
    Giovanella, Luca
    Suriano, Sergio
    Ricci, Riccardo
    Ceriani, Luca
    Verburg, Frederik Anton
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2011, 33 (04): : 552 - 556
  • [28] A randomized equivalence trial to determine the optimum dose of iodine-131 for remnant ablation in differentiated thyroid cancer
    Bal, Chandrasekhar
    Chandra, Prem
    Kumar, Ajay
    Dwivedi, Sadanand
    NUCLEAR MEDICINE COMMUNICATIONS, 2012, 33 (10) : 1039 - 1047
  • [29] Effectiveness of Reduced Radioiodine Activity for Thyroid Remnant Ablation after Total Thyroidectomy in Patients with Low to Intermediate Risk Differentiated Thyroid Carcinoma
    Todica, Andrei
    Haidvogl, Sabine
    Fendler, Wolfgang Peter
    Ilhan, Harun
    Rominger, Axel
    Haug, Alexander Robert
    Bartenstein, Peter
    Lehner, Sebastian
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2017, 56 (06): : 211 - 218
  • [30] Radioiodine uptake by thyroglossal duct remnant after radioiodine therapy for differentiated thyroid carcinoma
    Jinguji, M.
    Nakajo, M.
    Tani, A.
    Yoshiura, T.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S783 - S784